Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

Phillip C. Nguyen; Kate Manos; Chun Y. Fong; Anthony P. Schwarer; Ing S. Tiong; Andrew H. Wei; David Kliman; David J. Curtis

doi:10.1111/imj.15564

Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

Phillip C. Nguyen
, Kate Manos
, Chun Y. Fong
, Anthony P. Schwarer
, Ing S. Tiong
, Andrew H. Wei
, David Kliman
, David J. Curtis

Australian Centre for Blood Diseases

Research output: Contribution to journal › Article › Research › peer-review

Abstract

The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55–65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32% vs 33%, P = 0.90), as was relapse-free survival (23% vs 20%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.

Original language	English
Pages (from-to)	1954-1958
Number of pages	5
Journal	Internal Medicine Journal
Volume	51
Issue number	11
DOIs	https://doi.org/10.1111/imj.15564
Publication status	Published - Nov 2021

Keywords

acute myeloid leukemia
consolidation chemotherapy
elderly
haemopoietic stem cell transplantation
relapse
survival

Access to Document

10.1111/imj.15564

Cite this

@article{7a1116b2777f40edbc1e5af816f65836,

title = "Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission",

abstract = "The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55–65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32\% vs 33\%, P = 0.90), as was relapse-free survival (23\% vs 20\%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.",

keywords = "acute myeloid leukemia, consolidation chemotherapy, elderly, haemopoietic stem cell transplantation, relapse, survival",

author = "Nguyen, \{Phillip C.\} and Kate Manos and Fong, \{Chun Y.\} and Schwarer, \{Anthony P.\} and Tiong, \{Ing S.\} and Wei, \{Andrew H.\} and David Kliman and Curtis, \{David J.\}",

note = "Funding Information: Funding: David J Curtis is funded by a NHMRC Senior Research Fellowship APP1139466. Publisher Copyright: {\textcopyright} 2021 Royal Australasian College of Physicians.",

year = "2021",

month = nov,

doi = "10.1111/imj.15564",

language = "English",

volume = "51",

pages = "1954--1958",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell",

number = "11",

}

TY - JOUR

T1 - Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

AU - Nguyen, Phillip C.

AU - Manos, Kate

AU - Fong, Chun Y.

AU - Schwarer, Anthony P.

AU - Tiong, Ing S.

AU - Wei, Andrew H.

AU - Kliman, David

AU - Curtis, David J.

PY - 2021/11

Y1 - 2021/11

N2 - The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55–65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32% vs 33%, P = 0.90), as was relapse-free survival (23% vs 20%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.

AB - The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55–65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32% vs 33%, P = 0.90), as was relapse-free survival (23% vs 20%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.

KW - acute myeloid leukemia

KW - consolidation chemotherapy

KW - elderly

KW - haemopoietic stem cell transplantation

KW - relapse

KW - survival

UR - https://www.scopus.com/pages/publications/85119214889

U2 - 10.1111/imj.15564

DO - 10.1111/imj.15564

M3 - Article

C2 - 34796631

AN - SCOPUS:85119214889

SN - 1444-0903

VL - 51

SP - 1954

EP - 1958

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 11

ER -

Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

Abstract

Keywords

Access to Document

Other files and links

Curing blood cancers: rapid translation from target to drug to clinic

Cite this

Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

Abstract

Keywords

Access to Document

Other files and links

Projects

Curing blood cancers: rapid translation from target to drug to clinic

Cite this